Clinical Trials Logo

Peptic Ulcer clinical trials

View clinical trials related to Peptic Ulcer.

Filter by:

NCT ID: NCT00977678 Completed - Peptic Ulcer Clinical Trials

Drop in Gastroscopy - Experience After 9 Months

Start date: November 2009
Phase: N/A
Study type: Observational

The capacity for endoscopical procedures in the Norwegian health system is low in comparison to demands from patients and family practitioners. The studies aim is to evaluate the acceptance of a new concept: an open access gastroscopy clinic where patients can attend without a preceding appointment. The investigators wish to evaluate: 1. Patient´s satisfaction. 2. General practitioner´s satisfaction. 3. Acceptance by the staff of the clinic.

NCT ID: NCT00920400 Completed - Clinical trials for Inflammatory Bowel Diseases

Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract

Start date: March 2008
Phase: N/A
Study type: Observational

Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.

NCT ID: NCT00843063 Completed - Clinical trials for Peptic Ulcer/Erosions

Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Low-dose aspirin can prevent cerebral and cardiovascular accidents in individuals with symptomatic atherothrombotic disease, but its use is frequently limited by gastrointestinal side effects. The position of H2-receptor antagonists as a step-down therapy after healing of peptic ulcer or erosions by proton pump inhibitor is unclear. The objective of this randomized, double blinded control study was to compare the efficacy of high-dose famotidine with pantoprazole in the prevention of recurrent dyspeptic or complicated ulcer/ erosions in patients taking low-dose aspirin

NCT ID: NCT00840008 Completed - Clinical trials for Peptic Ulcer Hemorrhage

The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding

REASON-II
Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess whether adherence to NVUGIB guidelines is improved with implementation of a national, tailored multifaceted intervention. Outcomes include adherence rates to two key endoscopic and pharmacological therapy guidelines together (primary), or adherence to these individually as well as to other recommendations (secondary). Patient outcomes and economic data are also assessed (tertiary).

NCT ID: NCT00778193 Completed - Clinical trials for Gastroduodenal Ulcer

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Lesions2
Start date: October 2007
Phase: Phase 4
Study type: Interventional

Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal. As numerous patients already suffer from gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the treatment and management of these patients. The goal of this study is to investigate the effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal lesions in order to elucidate the mechanisms of ulcer healing. This single site, single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer healing through endoscopic, immunohistologic, and molecular PCR modalities.

NCT ID: NCT00745667 Completed - Clinical trials for Perforated Peptic Ulcer

The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction

LAMA
Start date: July 1999
Phase: N/A
Study type: Interventional

This is a multicenter trial comparing laparoscopic correction of a perforated peptic ulcer with the open technique by upper laparotomy. Hypothesis is that after laparoscopic correction will be discharged 3 days sooner due to less postoperative pain and complications.

NCT ID: NCT00731601 Completed - Clinical trials for Peptic Ulcer Hemorrhage

Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

PPI
Start date: May 2008
Phase: Phase 4
Study type: Interventional

A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.

NCT ID: NCT00624169 Completed - Clinical trials for Peptic Ulcer Perforation

Peptic Ulcer Perforation Study

PULP
Start date: November 2007
Phase: N/A
Study type: Interventional

The objective of this study is to implement an optimized perioperative course for patients surgically treated for peptic ulcer perforation in order to improve the outcome for these patients. The optimized perioperative course consists of a number of interventions carried out before, during and after surgery.

NCT ID: NCT00613665 Completed - Lymphoma Clinical Trials

Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults

Start date: February 2001
Phase: Phase 1
Study type: Interventional

This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine

NCT ID: NCT00573924 Completed - Clinical trials for Peptic Ulcer Hemorrhage

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

Start date: February 2006
Phase: N/A
Study type: Interventional

Patients with bleeding ulcers identified by endoscopy will be randomly assigned to receive an acid-blocking drug (called a proton pump inhibitor [PPI]) either by mouth every 3 hours for 24 hours or intravenously (IV) by constant infusion for 24 hours. A pH probe in the stomach will be used to determine intragastric pH (a measure of the acid production in the stomach) at baseline and during the 24 hours of therapy. The purpose of the study is to determine if the continuous intravenous administration of the drug provides better reduction of acid in the stomach than the oral administration.